Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
about
Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification.Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective studyImmunoprofile from tissue microarrays to stratify familial breast cancer patientsExpression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancerA miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study.Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers.Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.
P2860
Q33584106-416FF08D-AA61-47A9-9560-DC77D2845E25Q33664216-678691CF-0EE5-483B-BC48-3232066E8DACQ35168709-F97B7EC3-EC88-452F-B8CE-7C005F03838DQ35677713-8C7F2B81-91DA-465B-9257-1E633258FBABQ36288976-41466281-2D0E-4179-A45F-9A4CF71F50EDQ36413928-B2916122-5503-4902-9AD6-2C9B969562B8Q36898399-E25A750A-D6A8-4815-B823-5C1238FC3079Q37271711-A0422EE6-4B9D-438F-9384-14F412DDCA0AQ38409734-AE7FF4F0-5B27-4704-AFA7-02284271A73FQ41189272-46233E62-C384-45B0-B757-FF3E32799416Q41576606-ED5DDAD5-DA2E-45DB-820E-E639DD41B212Q48187446-5A796CE7-51D1-43EE-98C0-68126606D81AQ53192082-B939679D-AC72-4CCF-BF43-D2555C4ECBA5Q53291372-0FD7AF77-83FA-4E30-9ACC-A497FF5A2207Q54324778-8CABCEEB-6AC7-4C7D-92EA-2C9F74CDC9C1
P2860
Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Two histopathologically differ ...... n HER2-positive breast cancer.
@en
Two histopathologically differ ...... n HER2-positive breast cancer.
@nl
type
label
Two histopathologically differ ...... n HER2-positive breast cancer.
@en
Two histopathologically differ ...... n HER2-positive breast cancer.
@nl
prefLabel
Two histopathologically differ ...... n HER2-positive breast cancer.
@en
Two histopathologically differ ...... n HER2-positive breast cancer.
@nl
P2093
P2860
P1476
Two histopathologically differ ...... n HER2-positive breast cancer.
@en
P2093
Gyungyub Gong
Hee Jin Lee
In Ah Park
In Hye Song
Jin-Hee Ahn
Jong Han Yu
Joo Young Kim
Na Eun Kim
So Yeon Park
P2860
P2888
P304
P356
10.1007/S10549-014-2983-X
P407
P50
P577
2014-05-13T00:00:00Z